Primary study · included by 1 review

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

Buteau 2025 · Buteau James P, Kostos Louise, Jackson Price A, et al. · The Lancet Oncology · 2025

Included by

Non-Cochrane · intervention · 2026 · cited as Buteau 2025 · Reference list refs 21-53; Table 2; Supplementary Table 5

The review does not say which of its outcomes this study informs.

1 including review in total.